responsif GmbH announced today that it had been granted full patent protection for its proprietary polyomavirus-like-particle based NanosVir delivery technology by the United States Patent and Trademark Office. The newly issued patent now enhances the existing protection of responsif’s innovative technology platform also in the US, the world’s largest Biotech market. The novel US-patent (US 7,011,968) entitled ‘Fragments of virus protein 2 or 3 of the polyoma virus, used for transporting active ingredients’ protects the innovative NanosVir technology that can be applied to transport active ingredients (e.g. protein antigens) efficiently into cells. This key patent is central to the substantial patent portfolio and supplements responsif’s IP protection.
